What is Pennsaid Solution?
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body.
Pennsaid Solution 1% gel (Voltaren
Topical
) is used to treat joint pain in the hands, wrists, elbows, knees, ankles, or feet caused by osteoarthritis. This medication may not be effective in treating arthritis pain elsewhere in the body.Pennsaid Solution 1.5% solution (Pennsaid Solution) is used to treat pain in the knees caused by osteoarthritis. This medication may not be effective in treating arthritis pain elsewhere in the body.
Pennsaid Solution 3% gel (Pennsaid Solution) is used to treat warty overgrowths of skin (actinic keratoses) on sun-exposed areas of the body.
Pennsaid Solution may also be used for purposes not listed in this medication guide.
Pennsaid Solution indications
Pennsaid Solution® (diclofenac sodium) Gel is indicated for the topical treatment of actinic keratoses (AK). Sun avoidance is indicated during therapy.
How should I use Pennsaid Solution?
Use Pennsaid Solution solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Pennsaid Solution solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Pennsaid Solution solution refilled.
- Do not apply Pennsaid Solution solution to infected skin; open wounds; or red, swollen, or peeling skin.
- Wash your hands immediately before and after using Pennsaid Solution solution.
- Wash the affected area and dry completely before using Pennsaid Solution solution.
- To apply Pennsaid Solution solution, dispense 10 drops at a time onto the knee or into your hand. Spread Pennsaid Solution solution evenly around the front, back, and sides of the knee. Repeat until you have used the whole dose.
- Be sure that you cover your entire knee with your dose of Pennsaid Solution solution. Do not use more than the recommended amount.
- Do not apply sunscreens, cosmetics, insect repellants, other topical medicines, or any other substance to the treated area until it is completely dry.
- Do not put on clothes over the treated area until it is completely dry.
- Do not wrap, bandage, or apply heat to the treated area.
- Let the treated skin dry before touching it or letting it touch anyone else's skin.
- Do not shower, bathe, or wash the treated area for at least 30 minutes after you use Pennsaid Solution solution.
- If you miss a dose of Pennsaid Solution solution, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Pennsaid Solution solution.
Uses of Pennsaid Solution in details
Pennsaid Solution is used locally in the treatment of painful conditions such as arthritis of joint (osteoarthritis), conditions of the joint arising from destruction of healthy body tissue by the body’s immune system (rheumatoid arthritis, ankylosing spondylitis), lower back pain, sprains or bone fractures, inflammation of joints (frozen shoulder, gout), pain and swelling over body.
Pennsaid Solution description
Pennsaid Solution tablet also contains the following excipients: Core: Magnesium stearate, povidone, anhydrous colloidal silica, sodium starch glycollate, maize starch, calcium phosphate.
Sugar Coating: Microcrystalline cellulose, polyethylene glycol 8000, red iron oxide (E172) and titanium dioxide (E171) (dispersed Anstead), povidone, talc, sucrose.
Polish: Polyethylene glycol 8000, sucrose.
Imprint: Brown printing ink for 25 mg and white for 50 mg.
Diclofenac potassium is potassium-[0-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate.
In Pennsaid Solution, the sodium ion of diclofenac sodium (Voltaren) has been replaced by a potassium ion.
Pennsaid Solution dosage
Pennsaid Solution Dosage
Generic name: diclofenac sodium 30mg in 1g
Dosage form: gel
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Pennsaid Solution® Gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Pennsaid Solution® Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site. The recommended duration of therapy is from 60 days to 90 days. Complete healing of the lesion(s) or optimal therapeutic effect may not be evident for up to 30 days following cessation of therapy. Lesions that do not respond to therapy should be carefully re-evaluated and management reconsidered.
More about Pennsaid Solution (Pennsaid Solution)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 2 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Pennsaid Solution gel
- Pennsaid Solution
- Pennsaid Solution
Topical (Advanced Reading)
- Other brands: Voltaren Gel, Pennsaid Solution, Pennsaid Solution, Klofensaid II
Professional resources
- Pennsaid Solution topical (AHFS Monograph)
- Pennsaid Solution (FDA)
Related treatment guides
- Keratosis
Pennsaid Solution interactions
See also:
What other drugs will affect Pennsaid Solution?
Table 3: Clinically Significant Drug Interactions with Diclofenac
Drugs That Interfere with Hemostasis | |
Clinical Impact: |
|
Intervention: | Monitor patients with concomitant use of Pennsaid Solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding |
Aspirin | |
Clinical Impact: | Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone |
Intervention: | Concomitant use of Pennsaid Solution and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding. Pennsaid Solution is not a substitute for low dose aspirin for cardiovascular protection. |
ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers | |
Clinical Impact: |
|
Intervention: |
|
Diuretics | |
Clinical Impact: | Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. |
Intervention: | During concomitant use of Pennsaid Solution with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects. |
Digoxin | |
Clinical Impact: | The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. |
Intervention: | During concomitant use of Pennsaid Solution and digoxin, monitor serum digoxin levels. |
Lithium | |
Clinical Impact: | NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. |
Intervention: | During concomitant use of Pennsaid Solution and lithium, monitor patients for signs of lithium toxicity. |
Methotrexate | |
Clinical Impact: | Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction) |
Intervention: | During concomitant use of Pennsaid Solution and methotrexate, monitor patients for methotrexate toxicity. |
Cyclosporine | |
Clinical Impact: | Concomitant use of Pennsaid Solution and cyclosporine may increase cyclosporine’s nephrotoxicity. |
Intervention: | During concomitant use of Pennsaid Solution and cyclosporine, monitor patients for signs of worsening renal function. |
NSAIDs and Salicylates | |
Clinical Impact: | Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy Concomitant use of oral NSAIDs with Pennsaid Solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs. less than 1%), and more frequent abnormal creatinine (12% vs. 7%), urea (20% vs. 12%) and hemoglobin (13% vs. 9%). |
Intervention: | The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended. Do not use combination therapy with Pennsaid Solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations. |
Pemetrexed | |
Clinical Impact: | Concomitant use of Pennsaid Solution and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. |
Intervention: | During concomitant use of Pennsaid Solution and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration. |
Pennsaid Solution side effects
See also:
What are the possible side effects of Pennsaid Solution?
The following adverse reactions are discussed in greater detail in other sections of the labeling:
- Cardiovascular Thrombotic Events
- GI Bleeding, Ulceration and Perforation
- Hepatotoxicity
- Hypertension
- Heart Failure and Edema
- Renal Toxicity and Hyperkalemia
- Anaphylactic Reactions
- Serious Skin Reactions
- Hematologic Toxicity
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction ratesobserved in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In controlled trials during the premarketing development of Pennsaid Solution, approximately 600 patients with minor sprains, strains, and contusions were treated with Pennsaid Solution for up to two weeks.
Adverse Events Leading To Discontinuation Of Treatment
In the controlled trials, 3% of patients in both the Pennsaid Solution and placebo patch groups discontinued treatment due to an adverse event. The most common adverse events leading to discontinuation were application site reactions, occurring in 2% of both the Pennsaid Solution and placebo patch groups. Application site reactions leading to dropout included pruritus, dermatitis, and burning.
Common Adverse Events
Localized Reactions
Overall, the most common adverse events associated with Pennsaid Solution treatment were skin reactions at the site of treatment. Table 1 lists all adverse events, regardless of causality, occurring in ≥ 1% of patients in controlled trials of Pennsaid Solution. A majority of patients treated with Pennsaid Solution had adverse events with a maximum intensity of “mild” or “moderate.”
Table 1: Common Adverse Events (by body system and preferred term) in ≥ 1% of Patients treated with Pennsaid Solution or Placebo Patch
Category | Diclofenac N=572 | Placebo N=564 | ||
N | Percent | N | Percent | |
Application Site Conditions | 64 | 11 | 70 | 12 |
Pruritus | 31 | 5 | 44 | 8 |
Dermatitis | 9 | 2 | 3 | < 1 |
Burning | 2 | < 1 | 8 | 1 |
Other Includes: hypoesthesia, dizziness, and hyperkinesias. |
Foreign labeling describes that dermal allergic reactions may occur with Pennsaid Solution treatment. Additionally, the treated area may become irritated or develop itching, erythema, edema, vesicles, or abnormal sensation.
Pennsaid Solution contraindications
See also:
What is the most important information I should know about Pennsaid Solution?
Do not use this medication if you have ever had asthma or a severe allergic reaction caused by aspirin, diclofenac (Pennsaid Solution, Voltaren), or another non-steroidal anti-inflammatory drug (NSAID). Do not use diclofenac just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).
Before using this medication, tell your doctor if you have heart disease, congestive heart failure, high blood pressure, a history of heart attack or stroke, a history of stomach ulcer or bleeding, liver or kidney disease, a blood clotting disorder, asthma, or nasal polyps.
While the risk of absorbing Pennsaid Solution into your bloodstream is low, an NSAID may cause life-threatening heart or circulation problems such as heart attack or stroke, especially if you use it long term.
Get emergency medical help if you have chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.
This medicine may also cause serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and can occur without warning while you are using Pennsaid Solution, especially in older adults.
Call your doctor at once if you have symptoms of stomach bleeding such as black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.
Active ingredient matches for Pennsaid Solution:
List of Pennsaid Solution substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Pennsaid (Canada, Italy, Luxembourg, Portugal, United Kingdom, United States) | |
Pennsaid liquid 16.05 mg/mL (Dimethaid) | |
POWERFLAM PLUS | |
POWERFLAM PLUS 50 MG/500 MG TABLET 1 strip / 10 tablets each (Alkem Laboratories Ltd) | $ 0.20 |
Powerflam Plus 50 mg/500 mg Tablet (Alkem Laboratories Ltd) | $ 0.02 |
PRESTIGIN | |
PRESTIGIN GEL 1 tube / 30 GM gel each (Stadchem Of India) | $ 0.83 |
RECOFLAM | |
RECOFLAM GEL 1 tube / 30 GM gel each (Nectar Remedies Ltd) | $ 0.69 |
RECOFLAM INJECTION 1 vial / 3 ML injection each (Nectar Remedies Ltd) | $ 0.10 |
RECOFLAM SR TABLET 1 strip / 10 tablets each (Nectar Remedies Ltd) | $ 0.64 |
RECOFLAM TABLET 1 strip / 10 tablets each (Nectar Remedies Ltd) | $ 0.24 |
Recoflam NA Injection (Nectar Remedies Ltd) | $ 0.03 |
Recoflam S 50mg/10mg Tablet (Nectar Remedies Ltd) | $ 0.08 |
Recoflam NA Tablet (Nectar Remedies Ltd) | $ 0.02 |
Recoflam NA Tablet SR (Nectar Remedies Ltd) | $ 0.06 |
REMOB | |
REMOB GEL 1 tube / 30 GM gel each (Logos Pharma) | $ 0.78 |
RESINI | |
RESINI GEL 1 tube / 50 GM gel each (Resilient Cosmecueticals Pvt Ltd) | $ 1.02 |
RUBY (NEURON) | |
RUBY GEL 1 tube / 30 GM gel each (Neuro Pharma GmbH) | $ 0.78 |
SERRINI NANO IN | |
SERRINI NANO IN 1% GEL 1 tube / 12 GM gel each (Kamron Laboratories Ltd) | $ 1.07 |
Solaraze (Australia, Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Norway, Sweden, Switzerland, United Kingdom, United States) | |
Gel; Topical; Diclofenac Sodium 3% (Csl) | |
100 gram in 1 tube (Csl) | |
5 gram in 1 tube (Csl) | |
50 gram in 1 tube (Csl) | |
Solaraze gel 30 mg/g (Csl) | |
Solaraze Gel | |
TOPAC FAST | |
TOPAC FAST GEL 1 tube / 20 GM gel each (Abbott India Ltd) | $ 0.46 |
TRAUMANIL(RUI) | |
TRAUMANIL 1% GEL 1 tube / 30 GM gel each (Rusi Remedies P Ltd) | $ 0.65 |
VINI | |
VINI GEL 1 tube / 15 GM gel each (Kivi Labs Ltd) | $ 0.56 |
VITORIA | |
VITORIA 1.16% GEL 1 tube / 30 GM gel each (Bal Pharma Ltd) | $ 0.69 |
VOLITRA PLUS | |
VOLITRA PLUS SPRAY 1 packet / 55 GM spray each (Ranbaxy Laboratories Ltd) | $ 1.54 |
Voltaren Arthritis Pain Gel | |
Voltaren Topical | |
VOLYGEL | |
VOLYGEL CREAM 1 tube / 30 GM cream each (Morepen Laboratories Ltd) | $ 0.21 |
VOOMINI | |
VOOMINI GEL 1 tube / 30 GM gel each (Ind Swift Laboratories Ltd) | $ 0.21 |
VORIK | |
VORIK 1% GEL 1 tube / 30 GM gel each (Glenmark Pharmaceuticals Ltd) | $ 0.18 |
VORIK 50MG TABLET 1 strip / 10 tablets each (Glenmark Pharmaceuticals Ltd) | $ 0.78 |
Vorik 50mg Tablet (Glenmark Pharmaceuticals Ltd) | $ 0.08 |
VORIK PLUS 1% CREAM | |
VORIK PLUS 1% CREAM 1 tube / 30 GM cream each (Glenmark Pharmaceuticals Ltd) | $ 0.23 |
VOZOX | |
VOZOX 1% GEL 1 tube / 30 GM gel each (Mac Millon Pharmaceuticals Pvt Ltd) | $ 0.83 |
VOZOX TABLET 1 strip / 10 tablets each (Mac Millon Pharmaceuticals Pvt Ltd) | $ 0.51 |
Vozox NA Tablet (Mac Millon Pharmaceuticals Pvt Ltd) | $ 0.05 |
XEROFLAM ULTRA | |
XEROFLAM ULTRA 1% GEL 1 tube / 30 GM gel each (Helios Pharmaceuticals) | $ 1.08 |
Xrylix | |
Xrylix kit (Pure Tek Corporation (US)) | |
ZOOM(LAB) | |
ZOOM OINTMENT 1 tube / 25 GM ointment each (Laborate Pharmaceuticals India Ltd) | $ 0.40 |
See 197 substitutes for Pennsaid Solution |
References
- DailyMed. "DICLOFENAC EPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "diclofenac". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "diclofenac". http://www.drugbank.ca/drugs/DB00586 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Pennsaid Solution are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Pennsaid Solution. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology